SAMHSA Defunded Test Strips Three Weeks Before Arizona Posted a 17% Overdose Increase. The Timing Matters.

On April 24, SAMHSA sent a letter to federal grant recipients prohibiting the use of federal dollars for fentanyl and xylazine test strips, sterile syringes, and pipes distributed directly to people who use drugs. Funds can still flow to test strips used by public health departments, law enforcement, and clinicians in supervised settings — but the community-distribution model that drove the recent expansion in test-strip availability is now off-limits for SAMHSA dollars.

STAT News reported the agency described the change as a “clear shift away from harm reduction and practices that facilitate illicit drug use and are incompatible with federal law.” It is the first SAMHSA letter to use that framing since the agency began funding test-strip distribution in 2021.

The on-the-ground arithmetic

The Kentucky Harm Reduction Coalition is one example, but it is a useful one because the numbers are easy to read. The coalition lost a $400,000 SAMHSA grant — funding under which it had already distributed 48,465 fentanyl test strips in the first quarter of FY 2026. That is one organization, one quarter, one state. The national volume that just lost its funding source is large.

The American Society of Health-System Pharmacists filed formal opposition on April 30. Drug Policy Alliance is tracking the broader rollback.

Why this is on our Arizona watch

On May 13, the CDC released the data showing Arizona overdose deaths up 17.31% year-over-year while the nation declined 13.9%. Test strips do not solve an adulterated supply on their own. They do not stop polysubstance overdoses. But they do change the decisions people make in the moment — and at a moment when cychlorphine and other potent novel synthetics are entering the Southwest supply chain, removing one of the few real-time information sources users have is the wrong policy at the wrong time.

The full impact of the April 24 letter will not appear in CDC data until the August 2026 release window. For Arizona providers, advocates, and family members watching the trend, the right read is: the supply got harder and the safety net got smaller in the same six weeks. Both directions of that change matter.

For local distribution points still operating outside SAMHSA-funded channels, our Naloxone & Harm Reduction resources page is updated weekly with current Maricopa, Pima, and rural-county sources.